U.S. Food and Drug Administration said on Thursday it had approved Ranbaxy Laboratories' generic version of Novartis AG's blood pressure drug Diovan. Current market size of Diovan in the United States is $1.7 billion and Ranbaxy can generate revenue of over $200 million from generic Diovan sales as it enjoys 180 days exclusivity for the same.
It may be noted, Sun Pharma on April 7 agreed to buy Ranbaxy in an all-share deal, worth $4 billion.
It may be noted, Sun Pharma on April 7 agreed to buy Ranbaxy in an all-share deal, worth $4 billion.
